Over the past years, medical treatment for ccRCC has transitioned from a nonspecific immune approach to targeted therapy against vascular endothelial growth factor (VEGF) and now to novel immunotherapy agents (Garcia and Rini, 2007). Here, VEGFA is linked to nonpapillary renal cell carcinoma.